Anduril CEO says it's bad to IPO in ‘middle of a hype cycle’

Anduril’s CEO Brian Schimpf said the company is “not in a rush” to IPO in the current market, defining success as investors getting good returns three years after listing. He warned of a “hype cycle” and “crazy high valuations” as defense tech demand surges (U.S. defense budget on track for ~$1.5T) but the IPO market remains “tepid,” citing SpaceX’s post-offering drawdown (~25% from a ~$201.80 close to just above its ~$150 open). The article also notes OpenAI and Anthropic confidentially filed for IPOs without timelines while investors question whether public markets will pay ~*$1T*+ valuations, including Anduril’s May valuation doubling to ~$61B.

Analysis

The actionable signal is not about near-term defense demand; it is about capital formation delay. When founders explicitly prefer to wait for a better tape, the first-order winner is existing private holders, while public-market liquidity providers lose the near-term fee stream and the chance to anchor new comps. For NDAQ, that means the headline is more a timing issue than a fundamental issue: IPO revenue can be deferred rather than destroyed, but the next 1-2 quarters may remain soft if late-stage issuers keep sitting on the sidelines.

Second-order, the private defense-tech froth can actually help incumbents in the public market. If investors decide the private marks are too rich, procurement dollars may migrate toward established primes and public adjacent software names with cleaner cash flow and less valuation risk. That is bullish for listed defense exposure such as ITA constituents over 6-18 months, but bearish for anything that depends on a broad reopening of the IPO window to validate current private marks.

The contrarian point is that headline spending growth does not guarantee a healthy IPO cycle. If public investors keep discounting hype-cycle valuations, the market may demand a 20-30% haircut to private marks before rewarding new listings, which delays the cycle further. The thesis breaks if first-day performance and follow-on demand improve materially over the next 1-3 months, or if a marquee listing clears at a premium without immediate post-IPO decay.

Key Decisions for Investors

• Avoid chasing NDAQ on generic IPO optimism here; any benefit from deferred listings is a 2-4 quarter story, not a near-term earnings catalyst. Use rallies tied to AI/defense IPO headlines to trim, not add.
• Overweight ITA or a public-defense basket versus late-stage private defense exposure for the next 6-12 months; the market is more likely to reward visible cash-flow conversion than venture-style growth stories.
• Set a watch item on the next 2-3 major tech/defense IPOs: if first-week performance stays below deal price or post-IPO drawdowns persist, keep the IPO reopening trade off the table and fade any broker enthusiasm.
• If IPO issuance breadth improves and secondary trading stabilizes, consider a small tactical long in NDAQ; otherwise, the risk/reward remains poor until the window is clearly open.